Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation
Hu antigen R (HuR) is a central RNA‐binding protein regulating cell dedifferentiation, proliferation, and survival, which are well‐established hallmarks of cancer. HuR is frequently overexpressed in tumors correlating with tumor malignancy, which is in line with a role for HuR in tumorigenesis. Howe...
Saved in:
Published in | Hepatology (Baltimore, Md.) Vol. 55; no. 4; pp. 1237 - 1248 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.04.2012
Wiley Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Hu antigen R (HuR) is a central RNA‐binding protein regulating cell dedifferentiation, proliferation, and survival, which are well‐established hallmarks of cancer. HuR is frequently overexpressed in tumors correlating with tumor malignancy, which is in line with a role for HuR in tumorigenesis. However, the precise mechanism leading to changes in HuR expression remains unclear. In the liver, HuR plays a crucial role in hepatocyte proliferation, differentiation, and transformation. Here, we unraveled a novel mean of regulation of HuR expression in hepatocellular carcinoma (HCC) and colon cancer. HuR levels correlate with the abundance of the oncogene, murine double minute 2 (Mdm2), in human HCC and colon cancer metastases. HuR is stabilized by Mdm2‐mediated NEDDylation in at least three lysine residues, ensuring its nuclear localization and protection from degradation. Conclusion: This novel Mdm2/NEDD8/HuR regulatory framework is essential for the malignant transformation of tumor cells, which, in turn, unveils a novel signaling paradigm that is pharmacologically amenable for cancer therapy. (Hepatology 2012) |
---|---|
Bibliography: | This work was supported by NIH grant DK51719 (to S.C.L.). AT-1576 (to S.C.L., J.M.M. and M.L.M.-C.), AT004896 (S.C.L. and J.M.M.), SAF2005-00855 (to J.M.M. and M.L.M.-C) and ETORTEK-2011 (to M.L.M.-C); Programa Ramon y Cajal (to A.W., N.B. and A.C.), FIS PS09/00094 (to A.W.), FIS PS09/02010 (to N.B.), FIS Pl10/01484 (to A.C.) and FIS Pl11/01588 (to M.L.M.-C.); Sanidad Gobiemo Vasco 2009 (to M.L.M.-C. and F.J.B.); Education Gobierno Vasco 2011 (to M.L.M.-C.). Potential conflict of interest: Nothing to report. istex:A5FE1A8DAF946C87913E15F921DBABEA0000A626 ark:/67375/WNG-D84LTJXS-K ArticleID:HEP24795 This work was supported by NIH grant DK51719 (to S.C.L.). AT‐1576 (to S.C.L., J.M.M. and M.L.M.‐C.), AT004896 (S.C.L. and J.M.M.), SAF2005‐00855 (to J.M.M. and M.L.M.‐C) and ETORTEK‐2011 (to M.L.M.‐C); Programa Ramon y Cajal (to A.W., N.B. and A.C.), FIS PS09/00094 (to A.W.), FIS PS09/02010 (to N.B.), FIS Pl10/01484 (to A.C.) and FIS Pl11/01588 (to M.L.M.‐C.); Sanidad Gobiemo Vasco 2009 (to M.L.M.‐C. and F.J.B.); Education Gobierno Vasco 2011 (to M.L.M.‐C.). These authors contributed equally. fax: +34‐944‐061301 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0270-9139 1527-3350 |
DOI: | 10.1002/hep.24795 |